On November 16, shareholders of a small California biotech company voted to erase its identity entirely — abandoning oncology research in favor of decentralized artificial intelligence and blockchain infrastructure. The company, once called Qualigen Therapeutics, will ring in its new life as AIxCrypto Holdings at Nasdaq on November 20, now controlled by electric vehicle maker Faraday Future. It is a story as old as capital itself: the willingness to shed one purpose entirely in pursuit of a more luminous promise, with the question of who bears the cost left quietly unanswered.
The Manila Times
· Nov 16, 2025
· technology
· 5 min de leitura
High
Apuração: Caracterizado
Qualigen Rebrands as AIxCrypto, Pivots to AI-Web3 Platform Under Faraday Future Control
◉
Business
2799 artigos relacionados
Rocket Lab posts record revenue, eyes space data centres as next front…
The New Zealand Herald · 100% correspondência
Uber's Ride-Sharing Surge Fails to Impress Markets Amid Weak Profit Ou…
Google News · 90% correspondência
MACC arrests former CEO, CFO over RM370m plantation deal abuse of powe…
Malay Mail · 90% correspondência
Greggs Raises Profit Outlook Despite Supply Chain Disruption
Successful Farming · 90% correspondência
Honeywell Spin-off Solstice Pursues $14.5B Element Deal to Dominate AI…
Google News · 90% correspondência
Cobertura Relacionada
Memeburn · Aug 20
Google Hires Relay's Team as AI Automation Heads to Chrome
Google hired staff from shuttering AI automation startup Relay, including founder Jacob Bank, signaling plans to integra…
newsbreaks.infotoday.com · Aug 20 Lucidea Examines How Hybrid Work Is Reshaping Library ServicesLucidea examines how the shift from office-based to hybrid and remote work arrangements requires librarians to redesign …
CNBC · Aug 20 SK Hynix shares surge 12% on $28.7B buyback accelerationSK Hynix shares surged 12% after announcing acceleration of its 40 trillion won buyback program and expanding shareholde…
Seeking Alpha · Aug 20 Skellerup Holdings Posts Strong FY26 Results With 7% Revenue Growth, 25% ROICSkellerup Holdings delivered sustained revenue and earnings growth in FY2026, with 7% compound annual revenue growth and…
Viés e Enquadramento
⚖
Press release-style article presents corporate rebranding with promotional language; lacks critical analysis of biotech-to-crypto pivot risks or shareholder concerns.
Bias Direction
center-right
Confidence
HIGH
Promotional/corporate announcement framing that presents the transformation as a positive strategic move without scrutiny. Uses forward-looking language ('leading gateway,' 'strategic transformation') typical of investor relations materials.
strategic transformation
leading gateway to the AI × Web3 era
cross-ecosystem enablement
new business model, ecosystem structure, and three-year development roadmap
Critical analysis of the dramatic pivot from biotechnology to cryptocurrency/Web3
Shareholder concerns or dissenting voices
Industry expert commentary on viability of the business model shift
Regulatory considerations for crypto/Web3 operations
Financial performance data or risk assessment
Perspective from original Qualigen investors or employees
Competitive landscape analysis in AI-Web3 space
Impacto Geopolítico
🌎
A US biotech company's pivot to AI-Web3 under Chinese-linked control raises regulatory scrutiny concerns but has limited direct geopolitical impact.
Escalation Risk
low
Confidence
MED
United States
China
Global cryptocurrency markets
Chinese investors (YT Jia, Jerry Wang) gain significant influence over a NASDAQ-listed entity through Faraday Future's majority control (63% combined), potentially shifting tech sector dynamics in AI-Web3 space. This represents capital flow and strategic positioning in emerging tech sectors rather than traditional power realignment.
Similar to Chinese tech acquisitions of US companies in 2010s-2020s (e.g., Wanda Group's entertainment investments), though Web3/crypto adds regulatory complexity absent in traditional sectors.
Lente Econômica
📈
Qualigen Therapeutics rebrands to AIxCrypto Holdings, pivoting from biotech to AI-Web3 platforms under Faraday Future control, signaling speculative sector shift with high volatility risk.
Market Signal
mixed
Confidence
MED
Biotechnology/Pharmaceuticals
Cryptocurrency/Digital Assets
Artificial Intelligence
Electric Vehicles (Faraday Future)
Web3/Blockchain Technology
Uncertain impact on consumers. Existing biotech investors face significant portfolio risk from sector abandonment. Potential exposure to volatile crypto/AI markets. Limited direct consumer benefit until AI-Web3 platform specifics are revealed.
Likely regulatory scrutiny from SEC regarding shell company transformation and crypto exposure. May trigger biotech/pharmaceutical industry policy questions about abandoned R&D. Web3/crypto operations will face evolving regulatory frameworks. Potential shareholder protection reviews given majority control shift.